From Ancient Wisdom To Modern Oncology: How China's Cancer Drugs Are Quietly Rewriting India's Treatment Story

Nikunj May 10, 2026 420 Views

India's cancer care landscape is undergoing a silent but significant transformation. Chinese-origin immunotherapy drugs, entering the market through strategic Indian pharma partnerships, are slashing treatment costs by up to 70% — giving hope to millions of patients who could never afford Western medicine.

A Quiet Revolution In Indian Oncology

India has long grappled with a painful paradox: world-class cancer treatments exist, but remain financially out of reach for the majority. Western immunotherapy drugs, such as Keytruda (pembrolizumab), can cost upward of ₹5 lakh per cycle — an amount that routinely pushes Indian families into catastrophic debt. Now, a new wave of Chinese-origin drugs is disrupting this status quo, with major Indian companies like Dr. Reddy's, Glenmark, and Intas signing billion-dollar licensing deals to bring these affordable therapies to Indian patients.

The Drugs Making The Difference

Three Chinese-developed immunotherapy agents are at the forefront of this shift. Toripalimab (marketed as Zytorvi by Dr. Reddy's), Tislelizumab (Tevimbra), and Serplulimab (Heteroniflay) are PD-1 checkpoint inhibitors that work by unblocking the immune system's ability to detect and destroy cancer cells. These drugs are being used across a wide spectrum of cancers including lung, stomach, esophageal, nasopharyngeal, cervical, and head and neck cancers — offering treatment options where previously none existed.

The Cost Advantage

The price difference is staggering and clinically transformative. While American-origin immunotherapy can run ₹4–5 lakh per cycle, Chinese equivalents are available at a fraction of that cost — making multi-cycle treatment financially feasible for middle-income families. The Union Budget 2026-27 further amplified this relief by exempting customs duty on 17 critical cancer drugs, including Toripalimab, Tislelizumab, and Serplulimab, directly reducing their landed cost in India.

Treatment Access Insights

These are the key shifts shaping India's new cancer care reality:
Indian pharma majors Dr. Reddy's, Glenmark, and Intas are the primary licensees distributing Chinese immunotherapy brands nationally
Toripalimab (Zytorvi) is already commercially available for eligible cancer types, while Sintilimab awaits final regulatory clearance
Chinese biotech has also reduced CAR-T cell therapy costs from $475,000 globally to around $140,000, a 70% reduction, signalling broader innovation in affordable oncology
Budget 2026-27 removed customs duty on 17 cancer drugs, including multiple Chinese-origin immunotherapies, cutting out-of-pocket expenses for Indian patients
Doctors across major oncology centres confirm patients are responding positively to these therapies, with clinical outcomes comparable to more expensive Western counterparts

Beyond The Price Tag

Clinical efficacy, not just cost, is driving oncologist confidence in these drugs. China's biotech sector has matured rapidly, producing therapies that have been validated in large-scale Phase III trials and, in some cases, approved by stringent regulators in the US and Europe. China's own experience with making Trastuzumab accessible through national insurance negotiations — reducing costs by 61% overnight and doubling patient uptake within months — serves as a powerful proof-of-concept for what price intervention can achieve. As India aligns policy with need, these Chinese medicines may well become the cornerstone of affordable, modern oncology care for the 1.4 billion people who need it most.

Stay Ahead – Explore Now! Goa’s Gamble Halted: High Court Blocks Entry Of Massive Offshore Casino Ship